NCT06405490

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Conditions

• Nanoliposomal Irinotecan
• Cadonilimab
• Oxaliplatin
• Capecitabine
• First-Line
• Advanced Cancer
• Pancreatic Adenocarcinoma
• Drug Use

Interventions

Type	Name	Description
DRUG	Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab	Use the above medications on a regular basis

Timeline

• Start date: 2024-04-17
• Primary completion: 2026-08-30
• Completion: 2026-12-30
• First posted: 2024-05-08
• Last updated: 2024-12-24

Locations

1 site across 1 country: China